glp·helper
glphelper.com/semaglutide/texas/baytown
GLP-1 receptor agonistFDA-approved December 2017 (Ozempic) · June 2021 (Wegovy)Rx · Subcutaneous injection (weekly) · oral tablet (Rybelsus, daily) · Once weekly (injectable)

Semaglutide® providers &
prescriptions in Baytown, TX

Verified Semaglutide providers in Baytown, TX. Checked against the NPI registry, sorted by waitlist, not by who pays us.[7]

city providers
26
as of today
median wait
8d
first visit
telehealth
71%
of providers
cash range
$25 to $1,150
monthly
§ 02Provider directory: Texas
27 of 27 shown

Find a Semaglutide provider in Texas.

Every entry is checked against the NPI registry and the Texas medical board. Listings are ordered by current waitlist. The provider who can see you fastest appears first. We do not accept payment for placement.

Filter →
Type
Provider
City
Waitlist
Insurance
Browse by Texas city · /semaglutide/texas/{city}
§ 03Getting Semaglutide in Baytown
27 providers · Baytown, TX

How to get Semaglutide in Baytown.

27 GLP-1 prescribers and 7 local resource types are on record for Baytown, plus 3 nearby towns in the directory.

Prescribers in Baytown
27 prescribers
27 GLP-1 prescribers in Baytown, most listed as Family Medicine (14), Internal Medicine (7) and Internal Medicine, Endocrinology, Diabetes & Metabolism (3). Any Texas-licensed physician, nurse practitioner, or PA can prescribe Semaglutide, over video or in person. The nearest towns on record are La Porte (18 providers), Channelview (10 providers) and Deer Park (12 providers).
Around the prescription in Baytown
7 listed nearby
6 dietitians, 1 nutritionists, 6 gyms, 6 fitness clubs, 1 trainers, 6 physiotherapists and 2 places to move are on record near Baytown.
Medicaid (weight loss)
Diabetes only
As of April 2026, Texas Medicaid covers GLP-1s for diabetes but not for weight loss. Employer and private plans can still cover them; that is a plan-design choice, not a state rule.

Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm Texas’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.

§ 04Medication factsheet
cited · last review 2026.05.19

The molecule in Ozempic, Rybelsus, and Wegovy. The brands differ in approved use and maximum dose.

Semaglutide is a once-weekly GLP-1 receptor agonist sold under three brand names by Novo Nordisk: Ozempic and Rybelsus for type 2 diabetes, and Wegovy for chronic weight management. It mimics a gut hormone that signals satiety to the brain and slows gastric emptying. The injectable forms share the same molecule; only the approved indication and maximum dose differ.[2][3]

In the STEP-1 obesity trial, adults without diabetes taking Wegovy (semaglutide 2.4 mg) lost a mean of 14.9% of body weight at 68 weeks versus 2.4% with placebo. In the SELECT trial, semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in adults with overweight or obesity and established cardiovascular disease but without diabetes.[1]

At a glanceMultiple (brand-specific)
Generic name
semaglutide
Drug class
GLP-1 receptor agonist
Manufacturer
Novo Nordisk
FDA approved
December 2017 (Ozempic) · June 2021 (Wegovy)
Approved use
Type 2 diabetes (Ozempic/Rybelsus) · chronic weight management (Wegovy)
Off-label use
Use outside the approved brand/indication is off-label
Administration
Subcutaneous injection (weekly) · oral tablet (Rybelsus, daily) · Once weekly (injectable)
Available doses
0.25 mg · 0.5 mg · 1 mg · 1.7 mg · 2.4 mg
Half-life
≈ 7 days
Pregnancy
Discontinue ≥ 2 months before a planned pregnancy

Community health · CDC

Weight & metabolic health in Baytown

Baytown, Texas has a population of 83,701 people. The adult obesity rate in Baytown is an age-adjusted estimate of 39.7%, 4.1 percentage points above the Texas state rate of 35.6%. Diagnosed diabetes reaches 14.1% of adults in Baytown. Inactivity, meaning no leisure-time physical activity reported in the past month, affects 30.7% of adults in Baytown.

of Baytown adults have obesity
39.7%
diagnosed diabetes
14.1%
no regular physical activity
30.7%

Age-adjusted estimates for Baytown, community figures, not individual risk. CDC PLACES, 2025 release.

Estimate your weight lossthe science of Ozempic face
§ 05Support around Semaglutide in Baytown
6 gyms

The prescription is one part. Here is the rest, in Baytown.

Trials of semaglutide paired the drug with diet counseling and regular activity. Every name below is a real listing near Baytown, TX, ordered as the registry lists them, never by who pays us.

Gyms near you

A gym gives you the regular movement that keeps muscle while the weight comes off.

Fitness Connection
GYM
4.7 on Google · 2693 reviews
5035 Garth Rd
Website
Planet Fitness
GYM
4.5 on Google · 1063 reviews
6515 Garth Rd
Website
Bayway CrossFit
GYM
5.0 on Google · 273 reviews
5519 E Rd
Website
Species Gym
GYM
4.8 on Google · 204 reviews
1801 Decker Dr Ste A-160
Website
Anytime Fitness
GYM
3.8 on Google · 164 reviews
1414 W Fairmont Pkwy
Website
Forge Strength & Conditioning Gym
GYM
4.6 on Google · 101 reviews
11127 Gordon Speer Chambers Pkwy Ste 1800
Website

Fitness clubs and recreation centers

Fitness clubs and recreation centers run classes and pools, an easier start than a weight room.

La Porte Recreation and Fitness Center
REC CENTER
4.6 on Google · 129 reviews
1322 S Broadway St
Website
BellHouse CrossFit
FITNESS
5.0 on Google · 69 reviews
312 Bob Smith Rd
Website
Planet Fitness
FITNESS
4.3 on Google · 67 reviews
9253 Eagle Dr
Website
Sweat Club Mont Belvieu
FITNESS
5.0 on Google · 65 reviews
8830 FM 3180 Rd #301C
Website
Summit Athletics
FITNESS
4.6 on Google · 49 reviews
1806 S Battleground Rd Ste f
Website
Texas Made Boxing & Fitness
BOXING
4.6 on Google · 42 reviews
425 N 10th St
Website
§ 06Clinical evidence
STEP 1 to 4 + SELECT (N = 17,604)

What the trials actually showed.

We summarize the STEP weight-management program, the SUSTAIN diabetes program, and the SELECT cardiovascular outcomes trial. Figures are means at each trial's primary endpoint.

STEP-1 randomized 1,961 adults with overweight or obesity (without diabetes) to semaglutide 2.4 mg or placebo for 68 weeks. Mean weight change was −14.9% with semaglutide versus −2.4% with placebo; 86% of treated patients lost ≥5% of body weight.[2]
STEP / SELECT endpoint table2.4 mg / 68 wk
Mean weight change (Wegovy 2.4 mg)
−14.9%
STEP-1, 68 wk vs −2.4% placebo[2]
Patients losing ≥5% body weight
86%
STEP-1, 2.4 mg[2]
Major adverse cardiac events
−20%
SELECT, HR 0.80[3]
HbA1c reduction (T2D)
−1.4 to −1.8%
SUSTAIN program[4]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
average semaglutide weight loss →mapped to your starting weight
§ 07Safety & adverse events
from FDA label, sect. 6.1

Most side effects are gastrointestinal and resolve within weeks.

The most common adverse events in STEP trials were nausea (44%), diarrhea (30%), and vomiting (24%), more frequent at the 2.4 mg dose than at Ozempic doses, but typically transient.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[8]

Boxed warning. Boxed warning: risk of thyroid C-cell tumors. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
20 to 44%
mild
Most common; dose-dependent, usually eases after titration
Diarrhea
20 to 30%
mild
More frequent during dose escalation
Vomiting
16 to 24%
mild
Reduced by slower titration
Constipation
20 to 24%
mild
Abdominal pain
10%
moderate
Pancreatitis
<0.3%
serious
Discontinue if acute pancreatitis is suspected
Gallbladder disease
1.6 to 2.6%
serious
Cholelithiasis risk rises with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated with MTC or MEN-2 history
§ 08Cost & coverage, published, not gated
USD · monthly

Most directories hide the price. We don't.

Cash prices vary roughly 50× between the brand-name retail rate and a manufacturer savings card. The number you actually pay depends on your insurance plan, your diagnosis code, and which pharmacy fills the script. Here are the ranges, plainly.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk patient access program.

Cash, Wegovy (no insurance)
$1,300 to $1,400
per month
Brand-name retail average[6]
Cash, Ozempic (no insurance)
$950 to $1,150
per month
Brand-name retail average[6]
Commercial insurance (T2D)
$25 to $250
per month copay
Usually covered for diabetes with prior authorization
Commercial insurance (weight)
Often denied
Wegovy is on-label but frequently requires PA and is denied
Medicare Part D
$0 to $100
per month
T2D covered; weight-loss indication not covered by law[5]
Manufacturer savings card
as low as $0 to $25
per month
Commercial insurance only; eligibility limits apply
Updated weekly · last fetch 2026-05-18 04:00 UTCCost methodology →
Find Semaglutide providers in Texas

NPI-verified Semaglutide (semaglutide) prescribers and clinics, ordered by availability, never by who pays us.

Semaglutide in other states

Find NPI-verified Semaglutide (semaglutide) doctors, clinics, and pharmacies in the states we cover, ordered by availability, never by who pays us.

Related GLP-1 research
§ 09Frequently asked: Semaglutide in Texas

The questions people ask before they book.

Answers reviewed by the GLPHelper Medical Team. Citations link to primary sources, never marketing copy.

Yes. Semaglutide is the active molecule in all three Novo Nordisk products. Ozempic and Rybelsus are approved for type 2 diabetes; Wegovy is approved for chronic weight management at a higher maximum dose (2.4 mg/week). Insurers treat the brands as separate drugs.[1]